Research programme: VEGF receptor 2 antagonists - Astellas PharmaAlternative Names: Flk-1/KDR inhibitors - Astellas Pharma; YM-231146; YM-359445
Latest Information Update: 16 Jul 2016
At a glance
- Originator Astellas Pharma
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Japan (PO)
- 29 Sep 2006 Data presented at the 232nd American Chemical Society National Meeting (232nd-ACS-2006) have been added to the pharmacokinetics and the Cancer pharmacodynamics section
- 17 Jul 2006 A preclinical study has been added to the pharmacokinetics and Cancer pharmacodynamics sections